We postulate that the RJX-mediated suppression of TGF-β expression in the lungs will accelerate the resolution of pulmonary inflammation of COVID-19 patients by reducing the contributions of TGF-β to ARDS and its complications. The gene discussed is TGFB1; the disease is COVID-19.